Filtered By:
Condition: Atrial Fibrillation
Management: Funding
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Edoxaban versus enoxaparin –warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
Publication date: Available online 30 August 2016 Source:The Lancet Author(s): Andreas Goette, Jose L Merino, Michael D Ezekowitz, Dmitry Zamoryakhin, Michael Melino, James Jin, Michele F Mercuri, Michael A Grosso, Victor Fernandez, Naab Al-Saady, Natalya Pelekh, Bela Merkely, Sergey Zenin, Mykola Kushnir, Jindrich Spinar, Valeriy Batushkin, Joris R de Groot, Gregory Y H Lip Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled enoxaparin–warfarin therapy. Few safety d...
Source: The Lancet - August 30, 2016 Category: Journals (General) Source Type: research
Warfarin Use May Not Bring Long-Term Stability for Atrial Fibrillation
Contact: Amara Omeokwe Phone: 919-681-4239 Email:amara.omeokwe@duke.eduhttps://www.dukehealth.orgEMBARGOED FOR RELEASE until 11 a.m. (ET) on Tuesday, Aug. 9, 2016DURHAM, N.C. -- Warfarin prescribed to prevent strokes in atrial fibrillation may not adequately control blood clotting over the long-term, even when patients have been historically stable on the drug, according to a study from the Duke Clinical Research Institute.The findings, published Aug. 9 in the Journal of the American Medical Association (JAMA), are based on an 18-month study of 3,749 patients diagnosed with atrial fibrillation, an irregular heart rhythm. T...
Source: DukeHealth.org: Duke Health Features - August 9, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
Publication date: Available online 8 August 2016 Source:The Lancet Author(s): Jeff S Healey, Jonas Oldgren, Michael Ezekowitz, Jun Zhu, Prem Pais, Jia Wang, Patrick Commerford, Petr Jansky, Alvaro Avezum, Alben Sigamani, Albertino Demasceno, Paul Reilly, Alex Grinvalds, Juliet Nakamya, Akinyemi Aje, Wael Almahmeed, Andrew Moriarty, Lars Wallentin, Salim Yusuf, Stuart J Connolly Background Atrial fibrillation is an important cause of morbidity and mortality worldwide, but scant data are available for long-term outcomes in individuals outside North America or Europe, especially in primary care settings. Methods We did a coh...
Source: The Lancet - August 8, 2016 Category: Journals (General) Source Type: research
NICE wants GPs to prevent 8,000 strokes a year
New guidance could help identify atrial fibrillation Related items fromOnMedica Atrial fibrillation poses greater risk for women than men Never too old to benefit from CVD prevention Stroke can often be avoided, claims study Stroke rates rocket in younger men and women Dementia and stroke funding remains too low, say experts
Source: OnMedica Latest News - July 31, 2016 Category: UK Health Source Type: news
CardioNXT raises $1.5m for novel cardiac ablation tech
Heart focused medical-technology company CardioNXT said today it raised $1.5 million in equity funding to support its platform of cardiac arrhythmia products.
CardioNXT is developing products to improve the understanding of complex cardiac arrhythmias such as atrial fibrillation and to reduce the cost of cardiac catheter ablation procedures, the company said.
Funds in the round came from Solas BioVentures as well as existing investors in the Westminster, Colo.-based company.
“Our mission is to invest in solutions that enable people to lead longer and fuller lives. Atrial Fibrillation affects 6.1 million Americans a...
Source: Mass Device - May 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular CardioNXT Source Type: news
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
Publication date: Available online 4 April 2016 Source:The Lancet Author(s): Ziad Hijazi, Jonas Oldgren, Johan Lindbäck, John H Alexander, Stuart J Connolly, John W Eikelboom, Michael D Ezekowitz, Claes Held, Elaine M Hylek, Renato D Lopes, Agneta Siegbahn, Salim Yusuf, Christopher B Granger, Lars Wallentin Background The benefit of oral anticoagulation in atrial fibrillation is based on a balance between reduction in ischaemic stroke and increase in major bleeding. We aimed to develop and validate a new biomarker-based risk score to improve the prognostication of major bleeding in patients with atrial fib...
Source: The Lancet - April 4, 2016 Category: Journals (General) Source Type: research
Stroke Risk Stratification in Patients With Atrial Fibrillation Comme Ci, Comme Ça, Plus Ça Change… ∗
There has been a huge increase in academic interest in atrial fibrillation (AF) and particularly its major complication: thromboembolism. This sustained flurry of activity is fueled by the development of better thromboprophylaxis with well-controlled vitamin K antagonist (VKA) anticoagulation rather than antiplatelet therapy or poorly controlled management with VKAs. The emergence of new therapies, such as non-VKA oral anticoagulant agents and left atrial appendage occlusion devices with better net clinical benefit (less strokes, fewer intracranial or life-threatening bleeds, and reduced mortality) than with warfarin or as...
Source: Journal of the American College of Cardiology - October 19, 2015 Category: Cardiology Source Type: research
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research
Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial
Publication date: Available online 23 July 2015 Source:The Lancet Author(s): Laurent Macle, Paul Khairy, Rukshen Weerasooriya, Paul Novak, Atul Verma, Stephan Willems, Thomas Arentz, Isabel Deisenhofer, George Veenhuyzen, Christophe Scavée, Pierre Jaïs, Helmut Puererfellner, Sylvie Levesque, Jason G Andrade, Lena Rivard, Peter G Guerra, Marc Dubuc, Bernard Thibault, Mario Talajic, Denis Roy, Stanley Nattel Background Catheter ablation is increasingly used to manage atrial fibrillation, but arrhythmia recurrences are common. Adenosine might identify pulmonary veins at risk of reconnection by unmaski...
Source: The Lancet - July 29, 2015 Category: Journals (General) Source Type: research
Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study
Publication date: Available online 27 July 2015 Source:The Lancet Neurology Author(s): Linxin Li, Gabriel S Yiin, Olivia C Geraghty, Ursula G Schulz, Wilhelm Kuker, Ziyah Mehta, Peter M Rothwell Background A third of transient ischaemic attacks (TIAs) and ischaemic strokes are of undetermined cause (ie, cryptogenic), potentially undermining secondary prevention. If these events are due to occult atheroma, the risk-factor profile and coronary prognosis should resemble that of overt large artery events. If they have a cardioembolic cause, the risk of future cardioembolic events should be increased. We aimed to asses...
Source: The Lancet Neurology - July 28, 2015 Category: Neurology Source Type: research
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study
Publication date: Available online 7 May 2015 Source:The Lancet Author(s): Renate B Schnabel , Xiaoyan Yin , Philimon Gona , Martin G Larson , Alexa S Beiser , David D McManus , Christopher Newton-Cheh , Steven A Lubitz , Jared W Magnani , Patrick T Ellinor , Sudha Seshadri , Philip A Wolf , Ramachandran S Vasan , Emelia J Benjamin , Daniel Levy Background Comprehensive long-term data on atrial fibrillation trends in men and women are scant. We aimed to provide such data through analysis of the Framingham cohort over 50 years. Methods We investigated trends in incidence, prevalence, and risk factors for atrial fibrillat...
Source: The Lancet - May 9, 2015 Category: Journals (General) Source Type: research
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Publication date: Available online 11 March 2015 Source:The Lancet Author(s): Christian T Ruff , Robert P Giugliano , Eugene Braunwald , David A Morrow , Sabina A Murphy , Julia F Kuder , Naveen Deenadayalu , Petr Jarolim , Joshua Betcher , Minggao Shi , Karen Brown , Indravadan Patel , Michele Mercuri , Elliott M Antman Background New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vitamin K antagonists. A concern has emerged, however, that measurement of drug concentration or ...
Source: The Lancet - March 12, 2015 Category: Journals (General) Source Type: research
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Publication date: Available online 6 March 2015 Source:The Lancet Author(s): Jeffrey B Washam , Susanna R Stevens , Yuliya Lokhnygina , Jonathan L Halperin , Günter Breithardt , Daniel E Singer , Kenneth W Mahaffey , Graeme J Hankey , Scott D Berkowitz , Christopher C Nessel , Keith A A Fox , Robert M Califf , Jonathan P Piccini , Manesh R Patel Background Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Com...
Source: The Lancet - March 6, 2015 Category: Journals (General) Source Type: research
Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis
Publication date: Available online 4 March 2015 Source:The Lancet Neurology Author(s): Luciano A Sposato , Lauren E Cipriano , Gustavo Saposnik , Estefanía Ruíz Vargas , Patricia M Riccio , Vladimir Hachinski Background Among patients with atrial fibrillation, the risk of stroke is highest for those with a history of stroke; however, oral anticoagulants can lower the risk of recurrent stroke by two-thirds. No consensus has been reached about how atrial fibrillation should be investigated in patients with stroke, and its prevalence after a stroke remains uncertain. We did a systematic review and meta-analysis to estimat...
Source: The Lancet Neurology - March 5, 2015 Category: Neurology Source Type: research
Aligning Health Care Policy With Evidence-Based Medicine: The Case for Funding Direct Oral Anticoagulants in Atrial Fibrillation
Publication date: October 2014 Source:Canadian Journal of Cardiology, Volume 30, Issue 10 Author(s): James A. Stone , Karen M. Earl , Blair J. O'Neill , Mukul Sharma , Thao Huynh , Kori Leblanc , Richard Ward , Philip A. Teal , Jafna L. Cox Misalignment between evidence-informed clinical care guideline recommendations and reimbursement policy has created care gaps that lead to suboptimal outcomes for patients denied access to guideline-based therapies. The purpose of this article is to make the case for addressing this growing access barrier to optimal care. Stroke prevention in atrial fibrillation (AF) is discussed as a...
Source: Canadian Journal of Cardiology - November 1, 2014 Category: Cardiology Source Type: research
